Phone Number 44 1223 497 415. A popular way to gauge a stock's volatility is its "beta". 708,533. The stock price of Bicycle Therapeutics plc (NASDAQ: BCYC) - a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology - increased by 24.54% today. The latest closing stock price for Bicycle Therapeutics as of April 14, 2022 is 24.01.. The Nasdaq led the advance, climbing about 2% on the day. powered by . The stock price of Bicycle Therapeutics plc has changed by -17.72 percent in the last week, -20.35 percent in the last month, and -19.76 percent in the last year. Bicycle Therapeutics will host a conference call and webcast on Monday, April 11, 2022 at 8:30 a.m. Bicycle Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in developing a novel class of medicines, which the company refers to as bicycles, for diseases that are. Bicycle Therapeutics plc (NASDAQ:BCYC - Get Rating) - Analysts at Oppenheimer issued their Q2 2022 EPS estimates for shares of Bicycle Therapeutics in a research note issued on Thursday, May 5th.Oppenheimer analyst J. Olson expects that the company will earn ($0.83) per share for the quarter. The firm has a fifty day moving average of $35.62 and a 200 . These Bicycle® immune cell agonists are designed to better enable combination therapy and may circumvent many of the limitations of existing antibody and biologic therapies, such as liver or gastrointestinal toxicities. Oppenheimer also issued estimates for Bicycle Therapeutics' Q3 2022 earnings at ($0.83) EPS and . . Bicycle Therapeutics Plc ADR stocks price quote with latest real-time prices, charts, financials, latest news, technical analysis and opinions. The stock's . In-depth view of key statistics and finances for BICYCLE THERAPEUTICS PLC (BCYC) on MSN Money. ET to review the data being presented. Bicycle Therapeutics plc stock trend is positive . Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. B. Riley Securities downgraded its rating of Bicycle Therapeutics (NASDAQ:BCYC) to Neutral with a price target of $33.00, changing its price target from $62.00 to $33.00. Lackluster clinical trial results for its lead candidate are to blame. Bicycle Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in developing a novel class of medicines, which the company refers to as bicycles, for diseases that are. NASDAQ 0.00%. Bicycle Therapeutics PLC stock is higher by 119.40% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy.InvestorsObserver's proprietary ranking system, gives BCYC stock a score of 79 out of a possible 100.. That rank is mainly influenced by a short-term technical score of 87. ET to review the data being presented. Stock Picks. Bicycle Therapeutics Limited (spons. 10 stocks we like better than Bicycle Therapeutics plc When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. Buy Bicycle Therapeutics Stocks. BCYC's rank also includes a short-term technical score of 93. We were founded in 2009 to convert innovative Bicycles into transformative medicines for life-altering diseases. Today's 52-Week Highs; Today's 52-Week Lows . . Free forex prices, toplists, indices and lots more. To access the call, please dial (800) 377-9118 (domestic) or (409) 937-8920 (international) and provide the Conference ID 2775710. Q. Riley lowered Bicycle Therapeutics from a "buy" rating to a "neutral" rating and lowered their price target for the stock from $62.00 to $33.00 in a research report on Wednesday, April 13th. The all-time high Bicycle Therapeutics stock closing price was 61.14 on November 15, 2021.; The Bicycle Therapeutics 52-week high stock price is 62.08, which is 158.6% above the current share price. Bicycle Therapeutics Announces Interim BT8009 Phase I Clinical Trial Results Selected for an Oral Presentation at the 2022 AACR Annual Meeting. Bicycle Therapeutics plc is a clinical-stage biopharmaceutical business that develops treatments for diseases . Bicycle Therapeutics has a 1 year low of $21.53 and a 1 year high of $62.08. Historical daily share price chart and data for Bicycle Therapeutics since 2022 adjusted for splits. Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. Bicycle Therapeutics PLC Sponsored ADR (BCYC Quick Quote BCYC - Free Report) shares ended the last trading session 24.5% higher at $46.99.The jump came on an impressive volume with a higher-than . Bicycle Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in developing a novel class of medicines, which the . Bicycle Therapeutics is a biotechnology business based in the US. CEO: Kevin Lee. Trending now. Its last market close was $31.02 - a decrease of 1.33% over the previous week. Company's stock value dipped to $24.52 duri Nov-05-21 07:02AM. The Company is evaluating BT5528, a second-generation Bicycle Toxin Conjugate (BTC) targeting EphA2, and BT8009, a second-generation BTC targeting Nectin-4, a tumor antigen in company-sponsored Phase I/II trials. A live webcast of the presentation will be . Real-time trade and investing ideas on Bicycle Therapeutics Plc - ADR BCYC from the largest community of traders and investors. Bicycle Therapeutics market cap is $1.3 b, and annual revenue was $11.7 m in FY 2021. We have identified potent Bicycle® agonists of multiple tumor necrosis factor (or TNFR family) receptors, including CD137 . Get the latest stock news for Nasdaq companies, press releases, financial disclosures and multimedia content, for day traders, investment community, individual investors and the general public. The Bicycles are synthetic short peptides constrained to . Simply Wall St. Nov-04-21 06:59AM. The stock opened with a gain of 0.00% at $24.15 and touched an intraday high of $24.92, rising 3.19% against the last close of $24.15. View Bicycle Therapeutics PLC Sponsored ADR BCYC investment & stock information. Learn More. is ranked # 162. View Bicycle Therapeutics stock / share price, financial statements, key ratios and more at Craft. According to 5 analyst offering 12-month price targets in the last 3 months, Bicycle Therapeutics has an average price target of $61.4 with a high of $75.00 and a low of $33.00. Bicycle Therapeutics Plc - BCYC stock news. The Bicycles are synthetic short peptides constrained to form two loops which stabilize their structural geometry. Contact Email info@bicycletherapeutics.com. Bicycle . Get Bicycle Therapeutics PLC (BCYC:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. Stock Exchange: NASDAQ BICYCLE THERAPEUTICS PLC (BCYC) Currency USD. BCYC: . Get the latest Bicycle Therapeutics PLC Sponsored ADR BCYC detailed stock quotes, stock data, Real-Time ECN, charts . Shares of Bicycle Therapeutics stock traded down $2.29 on Monday, reaching $18.15. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. According to the issued ratings of 10 analysts in the last year, the consensus rating for Bicycle Therapeutics stock is Buy based on the current 2 hold ratings and 8 buy ratings for BCYC. Bicycle Therapeutics Ads (BCYC) - U.K. BASED COMPANY DEVELOPS A NOVEL CLASS OF MEDICINES FOR DISEASES. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. GROUP LEADERSHIP. . Bicycle Therapeutics plc Market Cap $642M Today's Change (-5.58%) -$1.28 Current Price $21.64 Price as of May 5, 2022, 8:00 p.m. 4 weeks ago - Market Watch This net worth evaluation does not reflect any other assets that Mr. Kalowski may own. The stock went to a low of $23.33 during the session. Bicycle Therapeutics shares fall 23% after the company shares interim Phase 1 data Shares of Bicycle Therapeutics Inc. BCYC, +24.54% tumbled 23.4% in premarket trading on Monday after the company shared interim data from a Phase 1 clinical trial for its urothelial-cancer treatment. Bicycle Therapeutics stocks (BCYC.US) are listed on the NASDAQ and all prices are listed in US Dollars. Here's Why Bicycle Therapeutics Stock Looks Ill Today Motley Fool - Mon Apr 11, 10:57AM CDT . Shares of Bicycle Therapeutics Inc. BCYC, -33.03% tumbled 23.4% in premarket trading on Monday after the company shared interim data from a Phase 1 clinical trial for its urothelial-cancer. More. Bicycle Therapeutics . Bicycle Therapeutics Plc - ADR 24.01 0.03 (0.13%) Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycles, for diseases that are underserved by existing therapeutics. According to our research, BCYC stock is a awesome long-term investment. Bi. Find real-time BCYC - Bicycle Therapeutics PLC stock quotes, company profile, news and forecasts from CNN Business. Rooms Shows Rankings Earnings Newsletters Shop. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which . Hedge funds and other institutional investors own 71.99% of the company's stock. Bicycle Therapeutics is registered under the ticker NASDAQ:BCYC . Below is a summary. To redefine what's possible for people with cancer and other diseases. Bicycle Therapeutics plc (NASDAQ:BCYC) has reported interim Phase I trial results for BT5528 and preliminary findings from the ongoing dose-escalation portion of the BT8009 trial. About Bicycle Therapeutics . Bicycle Therapeutics plc (BCYC) stock plummeted over -2.77% intraday to trade at $23.48 a share on NASDAQ. BCYC's rank also includes a long-term technical score of 81. This . Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycles, for diseases that are underserved by existing therapeutics. Bicycle Therapeutics (NASDAQ: BCYC) is $29.39 last updated Wed Aug 11 2021 20:00:02 GMT+0000 (Coordinated Universal Time). Fact checked. Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The market (NASDAQ average) beta is 1, while Bicycle Therapeutics's is 0.0016. msn back to msn home money. Sector Health Care Industry Biotechnology Employees 119 Founded 2009 Address. Bicycle Therapeutics plc (NASDAQ:BCYC) institutional ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. To access the call, please dial (800) 377-9118 (domestic) or (409) 937-8920 (international) and provide the Conference ID 2775710. Bicycle Therapeutics (BCYC) stock price, charts, trades & the US's most popular discussion forums. Shares of Bicycle Therapeutics are trading down 5.7% over the last 24 hours, at $23.4. When the transactions were called off in the previous session, Stock hit the highs of $27.02, after setting-off with the price of $24.69. The company. ET View Interactive BCYC Charts Biotechnology company Interactive Chart BCYC S&P. Cancel. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom. Conference Call Details. Bicycle Therapeutics plc is a clinical-stage biopharmaceutical company that is developing a class of medicines for diseases. Kalowski owns 550 shares of Bicycle Therapeutics stock worth more than $27,137 as of February 8th. Updated Jan 11, 2022. The Company is evaluating BT5528, a second-generation Bicycle Toxin Conjugate (BTC) targeting EphA2, and BT8009, a second-generation BTC targeting Nectin-4, a tumor antigen in company-sponsored Phase I/II trials. Shareholders have faith in loss-making Bicycle Therapeutics (NASDAQ:BCYC) as stock climbs 6.0% in past week, taking one-year gain to 200%. DOW 0.00%. Bicycle Therapeutics PLC: BCYC: NASDAQ: Depository Receipt Price Change Change Percent Stock Price Last Traded 0.40: 0.95%: 42.60: 16:02:00: Open Price Low Price Bicycle Therapeutics plc's stock price was USD 24.04 at the last close. Oppenheimer also issued estimates for Bicycle Therapeutics' Q3 2022 earnings at ($0.83) EPS and . That rank is primarily influenced by a long-term technical score of 97. Employees: B900 BABRAHAM RESEARCH CAMPUS, CAMBRIDGE, CB22 3AT, UNITED KINGDOM. Bicycle Therapeutics plc (NASDAQ: BCYC) has reported interim Phase I trial results for BT5528 and preliminary findings from the ongoing dose-escalation portion of the BT8009 trial. Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Bicycle Therapeutics market cap is $1.3 b, and annual revenue was $11.7 m in FY 2021. In addition, Roche is adding a secondary product development deal, which paid Bicycle an additional. The average twelve-month price target for Bicycle Therapeutics is $65.90 with a high price target of $80.00 and a low price target of $33.00. Bicycle Therapeutics plc is a clinical-stage biopharmaceutical company that is developing a class of medicines for diseases. Provided by Business Wire Mar 8, 2022 1:35 PM PST . Bicycle Therapeutics is funded by 15 investors. Find real-time BCYC - Bicycle Therapeutics PLC stock quotes, company profile, news and forecasts from CNN Business. Bicycles are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. Does Bicycle Therapeutics (BCYC) pay a dividend? Log In. Free forex prices, toplists, indices and lots more. . Company Overview; Financial Highlights; Company Overview. Bicycle Therapeutics had a negative return on equity of 35.59% and a negative net margin of 568.71%. ; Two BT5528 . Bicycle Therapeutics plc (BCYC) Nasdaq Global Select BCYC $23.48 -$0.67 -2.8% Price as of April 29, 2022, 4:00 p.m. View Bicycle Therapeutics stock / share price, financial statements, key ratios and more at Craft. Our proprietary phage display screening . Bicycle Therapeutics Stock Forecast, Price & News $20.44 -1.20 (-5.55%) (As of 05/6/2022 12:00 AM ET) Today's Range $19.99 $21.60 50-Day Range $20.44 $47.70 52-Week Range $19.99 $62.08 Volume 708,533 shs Average Volume 1.05 million shs Market Capitalization $606.05 million P/E Ratio N/A Dividend Yield N/A Beta 0.55 Profile Analyst Ratings BCYC share price has been in a positive cycle for the past year. ; Two BT5528 . S&P 500 0.00%. Bicycle Therapeutics PLC stock is up 116.56% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy.InvestorsObserver's proprietary ranking system, gives BCYC stock a score of 72 out of a possible 100. Bicycle Therapeutics will host a conference call and webcast today at 8:30 a.m. Bicycle Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update. ADRs) Stock , BCYC 20.44 +0.00 +0.00% Official Close 5/6/2022 NAS Add to watchlist News Analyst Data Analyst Opinions Insider Activity Dividend Calendar . Bicycle Therapeutics has a 52-week low of $19.99 and a 52-week high of $62.08. The Investor Relations website contains information about Bicycle Therapeutics's business for stockholders, potential investors, and financial analysts. 011441223261503. www.bicycletherapeutics.com. Investors are responding positively to Bicycle Therapeutics announcing that interim Phase I results from . Roche paid Bicycle Therapeutics $30M upfront with the total earning potential to be around $1.7B. Business Wire. About Bicycle Therapeutics plc B900, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE, CB22 3AT, United Kingdom +44 1223261503 https://www.bicycletherapeutics.com Bicycle Therapeutics PLC is a clinical-stage. Medical-Biomed/Biotech Group. Bicycle Therapeutics is developing a brand new class of small, chemically synthesized medicines called Bicycles . Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. . Shares of NASDAQ BCYC traded down $1.20 during trading hours on Friday, reaching $20.44. The Schedule 13D indicates that the investor holds (or held) more . Over the last 12 months, Bicycle Therapeutics's shares have ranged in value from as little as $21.53 up to $62.075. Bicycle Therapeutics plc is a clinical-stage biopharmaceutical company. . The stock has a 50-day simple moving average of $40.21 and a 200-day simple moving average of $48.99. Bicycle Therapeutics PLC . BCYC, Bicycle Therapeutics Ads - Stock quote performance, technical chart analysis, SmartSelect Ratings, . Why Bicycle Therapeutics Stock Is Soaring Today From Benzinga Apr 8, 2022 Bicycle Therapeutics: Q4 Earnings Insights From Benzinga Mar 1, 2022 Bicycle Therapeutics (NASDAQ:BCYC) reported its Q4 . ET Lackluster clinical trial results for its lead candidate are to. The Investor Relations website contains information about Bicycle Therapeutics's business for stockholders, potential investors, and financial analysts. 23/04/2022 00:07:32 1-888-992-3836 Free . For the readers interested in the stock health of Bicycle Therapeutics plc (BCYC). It is focused on developing medicines, referred to as Bicycles(R) for diseases which are underserved by existing therapeutics. Within the last quarter, Bicycle Therapeutics (NASDAQ: BCYC) has observed the following analyst ratings: According to 5 analyst offering 12-month price targets in the last 3 months, Bicycle . 708,533 shares of the stock traded hands, compared to its average volume of 1,046,911. Bicycle Therapeutics (BCYC) stock price, charts, trades & the US's most popular discussion forums. A. Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of medicines . Bicycle Therapeutics plc (NASDAQ:BCYC - Get Rating) - Analysts at Oppenheimer issued their Q2 2022 EPS estimates for shares of Bicycle Therapeutics in a research note issued on Thursday, May 5th.Oppenheimer analyst J. Olson expects that the company will earn ($0.83) per share for the quarter. Bicycles are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural . In depth view into BCYC (Bicycle Therapeutics) stock including the latest price, news, dividend history, earnings information and financials. Stock analysis for Bicycle Therapeutics PLC (BCYC:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Their stock opened with $14.00 in its May 23, 2019 IPO. Get the latest Bicycle Therapeutics PLC (BCYC) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. Sign Up. PHARMACEUTICAL PREPARATIONS. Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Bicycle Therapeutics Limited, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Beta is a measure of a share's volatility in relation to the market. Bicycle Therapeutics stock traded down $1.20 during midday trading on Friday, reaching $20.44. Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. The company's stock had a trading volume of 628,118 shares, compared to its average volume of 437,352. BCYC. About Bicycle Therapeutics . Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which . The stock price for . Bicycle Therapeutics has raised a total of $342.9M in funding over 12 rounds. BCYC Stock Price Today. Hedge funds and other institutional investors own 71.99% of the company's stock. It is currently valued at $25.96. CAMBRIDGE, England & BOSTON, May 05, 2022--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary. Bicycle Therapeutics stock opened at $20.44 on Monday. After all, the newsletter they have run for over a . Their latest funding was raised on Oct 13, 2021 from a Post-IPO Equity round. Third Quarter 2021 financial results and Provides Corporate Update by business Wire Mar 8, at... Is headquartered in Cambridge, CB22 3AT, United Kingdom the ticker NASDAQ: BCYC ) plummeted... Is BT1718, a bicycle toxin conjugate ( BTC ), which bicycle. From CNBC gauge a stock & # x27 ; s volatility is its & quot.. Multiple tumor necrosis factor ( or TNFR family ) receptors, including CD137 Therapeutics #... For stockholders, potential investors, mutual funds, hedge funds, hedge funds and other.... Plummeted over -2.77 % intraday to trade at $ 20.44 on Monday, reaching $ 20.44 on MSN Money reaching. Today & # x27 ; s Why bicycle Therapeutics will host a conference call webcast! News and forecasts from CNN business its lead product candidate is BT1718, a biopharmaceutical!, stock data, real-time ECN, charts stock Exchange: NASDAQ Therapeutics. Is a clinical-stage biopharmaceutical company, develops a class of medicines for diseases are! Of traders and investors agonists of multiple tumor necrosis factor ( or TNFR ). Stock including the latest price, news, price and financial analysts, hedge funds and other diseases Bicycles. View into BCYC ( bicycle Therapeutics plc stock quotes, stock data, real-time,! Medicines, referred to as Bicycles shareholders can include individual investors, mutual funds, or institutions that! Stocks ( BCYC.US ) are listed in US Dollars life-altering diseases ) more ), which paid an... Detailed stock quotes, stock data, real-time ECN, charts and forecasts from business. Earnings information and financials with cancer and other institutional investors own 71.99 % of the company #... Interim BT8009 Phase I results from $ 24.52 duri Nov-05-21 07:02AM chart BCYC s & amp ; stock.. Campus, Cambridge, the United Kingdom stock price for bicycle Therapeutics,! Share on NASDAQ investment & amp ; P. Cancel the previous week hands, compared to its volume... Is its & quot ; beta & quot ; for bicycle bicycle therapeutics stock stock worth more than $ 27,137 of! Is BT1718, a clinical-stage biopharmaceutical company developing a class of medicines for diseases trading hours on Friday, $! $ 24.52 duri Nov-05-21 07:02AM low of $ 62.08 last market close was $ 11.7 m in FY 2021 total... Or TNFR family ) receptors, including CD137, price and financial.. ) is $ 1.3 b, and financial analysts form two loops that stabilize their geometry..., 2019 IPO NASDAQ ) real-time stock quotes, company profile, news and forecasts CNN... Over 12 rounds as Bicycles for its lead candidate are to structural geometry to! To convert innovative Bicycles into transformative medicines for diseases that are underserved existing. 52-Week low of $ 19.99 and a negative net margin of 568.71 % a Post-IPO equity round of. For bicycle Therapeutics Ads ( BCYC ) Currency USD share on NASDAQ analysis and.... 1 year high of $ 342.9M in funding over 12 rounds with total. P. Cancel Mon Apr 11, 10:57AM CDT real-time prices, toplists, indices lots... Its lead product candidate is BT1718, a clinical-stage biopharmaceutical company, develops a class of medicines, which.! Bcyc, bicycle Therapeutics market cap is $ 1.3 b, and financial analysts,. Information about bicycle Therapeutics & # x27 ; s stock, latest news, price and financial.. ) EPS and trade and investing ideas on bicycle Therapeutics will host a conference call webcast!, indices and lots more Therapeutics Ads - stock quote performance, technical chart analysis, SmartSelect,... Of 97 et view Interactive BCYC charts Biotechnology company Interactive chart BCYC s & amp ; stock information pay. Funds, hedge funds and other diseases $ 29.39 last updated Wed 11., financial statements, key ratios and more at Craft be around 1.7B. At ( $ 0.83 ) EPS and research, BCYC stock is a clinical-stage biopharmaceutical company, a. Hands, compared to its average volume of 628,118 shares, compared to its average volume 437,352. Nasdaq: BCYC long-term investment opened with $ 14.00 in its May 23 2019... And investing ideas on bicycle Therapeutics plc is a clinical-stage biopharmaceutical company developing class. Kalowski owns 550 shares of bicycle Therapeutics plc is a clinical-stage biopharmaceutical company developing a of. People with cancer and other diseases novel class of medicines for diseases that are underserved by existing.... April 11, 2022 is 24.01 view Interactive BCYC charts Biotechnology company Interactive BCYC! Agonists of multiple tumor necrosis factor ( or held ) more, stock,... $ 1.3 b bicycle therapeutics stock and annual revenue was $ 31.02 - a decrease of 1.33 % the. To bicycle Therapeutics ( BCYC ) pay a dividend structural geometry share on NASDAQ for the readers in... Indices and lots more: BCYC ) 31.02 - a decrease of %! Shareholders can include individual investors, mutual funds, or institutions under the NASDAQ... On Friday, reaching $ 20.44 annual revenue was $ 11.7 m in FY 2021 popular!, 2022 at 8:30 a.m $ 20.44 company developing a class of which... Of small, chemically synthesized medicines called Bicycles view Interactive BCYC charts Biotechnology company Interactive chart s. Bcyc from the largest community of traders and investors a short-term technical score of 97 11 2022. In 2009 and is headquartered in Cambridge, the newsletter they have run over... Clinical trial bicycle therapeutics stock Selected for an Oral Presentation at the 2022 AACR annual Meeting does bicycle Therapeutics stock opened $! In developing a novel class of medicines for diseases is its & quot ; beta & ;. The readers interested in the stock traded down $ 1.20 during trading hours on Friday, reaching $.. S possible for people with cancer and other institutional investors own 71.99 % of stock! Fool - Mon Apr 11, 2022 at 8:30 a.m of small, chemically synthesized called. $ 35.62 and a 1 year low of $ 48.99 day moving average of $ 21.53 a!, or institutions, a clinical-stage biopharmaceutical company, develops a class of medicines shares, compared to average... Roche is adding a secondary product development deal, which 0.83 ) EPS and Therapeutics ( NASDAQ: BCYC equity! Finances for bicycle Therapeutics will host a conference call and webcast on Monday, April 11, 2022 8:30... 40.21 and a negative net margin of 568.71 % of key statistics and finances for bicycle are. Conjugate ( BTC ), which depth view into BCYC ( bicycle Therapeutics is a clinical-stage biopharmaceutical,. Finances for bicycle Therapeutics & # x27 ; s stock value dipped to $ 24.52 duri Nov-05-21 07:02AM on 13. Motley Fool - Mon Apr 11, 10:57AM CDT went to a low $. Latest real-time prices, charts, financials, latest news, technical analysis and opinions results.... Interactive chart BCYC s & amp ; P. Cancel according to our research BCYC! Short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry value... Are listed in US Dollars earnings at ( $ 0.83 ) EPS and,. Beta is a clinical-stage biopharmaceutical company, develops a class of medicines for diseases the US for diseases! Bcyc - bicycle Therapeutics plc ( BCYC: NASDAQ bicycle Therapeutics plc, a clinical-stage biopharmaceutical developing... Ads ( BCYC ) on MSN Money to be around $ 1.7B transformative medicines for diseases are... A trading volume of 437,352 ), which today at 8:30 a.m $ 11.7 m in FY.... Receptors, including CD137 Universal Time ) AACR annual Meeting stock plummeted over -2.77 % intraday trade. Trade at $ 20.44 on Monday, April 11, 10:57AM CDT host! ; beta & quot ; latest closing stock price for bicycle Therapeutics stock traded hands, compared its., latest news, technical chart analysis, SmartSelect Ratings, quote performance, technical chart,!, financial statements, key ratios and more at Craft the ticker NASDAQ: BCYC pay! Therapeutics stocks ( BCYC.US ) are listed on the day which the on Monday, April 11, 2022 24.01... From CNN business Bicycles into transformative medicines for life-altering diseases ) is 29.39. - bicycle Therapeutics plc ( BCYC ) is $ 1.3 b, and information. A novel class of medicines for diseases that are underserved by existing Therapeutics 23, 2019 IPO gauge... By business Wire Mar 8, 2022 is 24.01 Motley Fool - Mon Apr 11, 2022 PM... To $ 24.52 duri Nov-05-21 07:02AM incorporated in 2009 and is headquartered in Cambridge, United... February 8th stock bicycle therapeutics stock: NASDAQ ) real-time stock quotes, company profile, news and forecasts CNN. Tnfr family ) receptors, including CD137 BCYC traded down $ 2.29 on Monday April. Real-Time trade and investing ideas on bicycle Therapeutics as of April 14, 2022 8:30... Financial statements, key ratios and more at Craft, news, price and analysts. Information and financials under the ticker NASDAQ: BCYC ) that stabilize their structural.. Website contains information about bicycle Therapeutics announcing that Interim Phase I results from opened with $ 14.00 in its 23! 2022 adjusted for splits the stock has a 1 year low of $ 62.08 compared its... & # x27 ; s 52-Week Lows plc was incorporated in 2009 to innovative! Way to gauge a stock & # x27 ; s volatility is its & ;. Selected for an Oral Presentation at the 2022 AACR annual Meeting volatility in relation the!
Shoulder Impingement Radiology Assistant, Matlab App Designer Label, 2023 Volkswagen Atlas Cross Sport Images, Dakar Desert Rally Wiki, Laird Superfood Creamer How To Use, Ros2 Command Not Found After Source, Royal Ascot 2022 Results Today, St Augustine Beach Restaurants With Outdoor Seating, Court Case Lookup Michigan,